Hayley Virgil

Treatment with trifluridine/tipiracil plus bevacizumab trended towards favorability despite not demonstrating statistically significant superiority in patients with metastatic colorectal cancer.

Treatment with an aromatase inhibitor appears to reduce the risk of breast cancer recurrence in patients who are premenopausal and undergoing ovarian suppression vs tamoxifen.

The phase 3 SIENDO trial, examining the use of frontline maintenance selinexor after combination chemotherapy in patients with advanced or recurrent endometrial cancer, met its primary end point of a statistically significant improvement in progression-free survival.

Patients with PD-1/PD-L1–refractory metastatic non–small cell lung cancer did not achieve additional benefit when radiotherapy was added to durvalumab and tremelimumab.

The 2021 United States Preventive Services Task Force lung cancer screening criteria changes successfully reduced racial disparities in eligibility by broadening screening eligibility criteria.

In recognition of World Cancer Day, CancerNetwork® spotlights NCCN efforts to reduce disparities in cervical cancer.

For World Cancer Day, CancerNetwork® reviews key highlights from the Cancer Facts & Figures 2022 report from the American Cancer Society, with updates in cancer incidence, mortality, and survival across patient subgroups.

Abiraterone acetate and luteinizing hormone–releasing hormone agonist is a promising second-line option for androgen receptor–expressing castration resistant salivary gland cancer.

Umbralisib is currently under investigation by the FDA regarding a potentially increased risk of death in patients with lymphomas following data from an ongoing trial investigating its use in chronic lymphocytic leukemia.

Prescription of an appropriate duration of antivirals for the prevention of Varicella-Zoster virus reactivation in patients with multiple myeloma has notable importance, with experts emphasizing a need to adhere to treatment guidelines.

Due to an imbalance of investigator-reported unexpected adverse reactions, the FDA placed a partial clinical hold on all trials examining the combination of magrolimab and azacitidine in acute myeloid leukemia and myelodysplastic syndrome.

The FDA has placed a partial clinical hold on trials using umbralisib and ublituximab as a treatment for chronic lymphocytic leukemia and non-Hodgkin lymphoma.

CUE-101 could be a potentially promising therapeutic agent for patients with recurrent/metastatic, HPV16-positive head and neck squamous cell carcinoma.

A new drug application for parsaclisib to treat relapsed/refractory mantle cell lymphoma, marginal zone lymphoma, and follicular lymphoma has been withdrawn.

The European Commission approves the use of lorlatinib for the treatment of ALK-positive advanced non–small cell lung cancer.

A label update for the CAR T-cell therapy product axicabtagene ciloleucel has been approved by the FDA to allow for use of prophylactic corticosteroid to manage cytokine release syndrome.

In a regulatory update on cemiplimab for advanced cervical cancer, Regeneron Pharmaceuticals announced that the agent’s biologics license application has been withdrawn.

SNIPR001 has received a fast track designation by the FDA for the prevention of blood infections in patient with hematologic malignancies.

Tislelizumab met the primary end point of overall survival in the phase 3 RATIONALE 305 trial in a population of patients with locally advanced unresectable/metastatic gastric or gastroesophageal junction cancer with a PD-L1–expressing tumor in the first-line setting.

Investigators believe that low-dose CT screenings should only be offered to heavy smokers after identifying an association between the diagnostic and an overdiagnosis in nonsmoking Asian women.

Topline findings from the phase 3 MOMENTUM study indicated that patients with myelofibrosis experienced a statistically significant reduction in symptoms following treatment with momelotinib.

In an interview with CancerNetwork, Don Dizon, MD, FACP, FASCO, discusses key updates that read out in both the gynecologic oncology and breast cancer fields over the course of 2021.

The supplemental biologics license application for cemiplimab plus chemotherapy for patients with advanced non–small cell lung cancer was based on findings from the phase 3 EMPOWER-Lung 3 study and was accepted for review by the FDA.

Pemigatinib is a new treatment option following approval from the Hong Kong Department of Health for patients with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement following progression on at least 1 prior line of therapy.

Patients with heavily pretreated metastatic uveal melanoma appeared to benefit from treatment with a synthetic lethal combination of darovasertib and crizotinib.

The phase 1b KOMET-001 trial, examining the use of KO-539 in patients with relapsed or refractory acute myeloid leukemia, will continue following authorization from the FDA.

Patients with advanced hepatocellular carcinoma achieved notable improvements in survival and responses following treatment with transarterial chemoembolization and lenvatinib.

Sugemalimab showed promise in the phase 2 GEMSTONE-201 trial in a group of patients with extranodal natural killer/T-cell lymphoma; developer CStone is set to submit a new drug application for the treatment to the National Medical Products Administration of China.

Gilead Sciences has announced the voluntary withdrawal of idelisib from the United States market in several indications including follicular lymphoma and small lymphocytic leukemia.

In this episode of "Oncology Peer Review On-The-Go," Amy Comander, MD, spoke with CancerNetwork regarding important developments in breast cancer that took place in 2021 and key clinical trials that read out throughout the year.